AMENDMENTS TO THE CLAIMS

A marked-up version of the claims that will be pending following entry of the present amendments showing the amendments made herein follows. Matter that has been deleted from the claims is indicated by strikethrough and matter that has been added is indicated by underlining.

Please enter the following amended claims:

40. (Currently Amended) A method for inhibiting human immunodeficiency virus (HIV) replication in a patient harboring said HIV comprising administering to the patient a combination comprising:

at least one first compound exhibiting α_1-antitrypsin (AAT) [or AAT]-like activity, wherein said compound exhibiting AAT-like activity is a non-natural molecule comprising Benzyloxycarbonyl-L-valyl-N-[1-(2-(3-methylbenzyl)-1,3,4-oxadiazolyl]carbonyl)-2-(S)-methylpropyl]-L-prolinamide (CE-2072) or a derivative thereof that upon administration to a patient in need thereof, inhibits serine protease[, with the exception that the first compound is not serine leukocyte protease inhibitor]; and

at least one second compound selected from the group consisting of HIV reverse transcriptase inhibitors and HIV protease inhibitors, for a time and under conditions effective to inhibit HIV replication.

46. (Currently Amended) A method of inhibiting human immunodeficiency virus (HIV) replication comprising administering to a patient in need thereof, a combination of at least one compound exhibiting α_1-antitrypsin (AAT) [or AAT]-like activity and one or more compounds selected from a group consisting of HIV reverse transcriptase inhibitors and HIV protease inhibitors, for a time and under conditions effective to inhibit HIV replication, wherein said compound exhibiting AAT-like activity is a non-natural molecule comprising Benzyloxycarbonyl-L-valyl-N-[1-(2-(3-methylbenzyl)-1,3,4-oxadiazolyl]carbonyl)-2-(S)-methylpropyl]-L-prolinamide (CE-

2072) or a derivative thereof that, upon administration to a patient in need thereof, inhibits serine protease[, and with the exception that the compound exhibiting α_1-antitrypsin activity is not serine leukocyte protease inhibitor].

47. The method of claim 40, wherein said first compound is a non-natural or man-made molecule.

49. (Canceled)